The long-term trend of the EPS is an important number as it indicates the present value of Autolus Therapeutics. The EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been 15.40 % over the last twelve months. EPS growth is a vital measure of execution of the strategy for Autolus Therapeutics since it indicates how well the business is allocating resources to benefit shareholders.
Autolus Therapeutics is in the biotechnology industry and trades as part of the healthcare sector. The company CEO is Christian Itin. Autolus Therapeutics is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company’s pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and AUTO6.
Previous Intraday Performance:
The AUTL shares had a previous change of 0.62% which opened at 38.71 and closed at 39.02. It moved to an intraday high of 40.69 and a low of 38.22.
Historical Performance:
Over the last five trading days, AUTL shares returned -4.55% and in the past 30 trading days it returned 24.86%. Over three months, it changed 32.27%. In one year it has changed 56.08% and within that year its 52-week high was 53.24 and its 52-week low was 19.17. AUTL stock is 103.51% above its 52 Week Low.
Our calculations result in a 200 day moving average of 0.00 and a 50 day moving average of 31.91. Right now, AUTL stock is trading inf% above its 200 day moving average and may be a good opportunity to buy.
PR Newswire: Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)
Liquidity:
The company has a market cap of $1.6b with 40.1m shares outstanding and a float of 40.1m shares. Trading volume was 56,218 shares and has experienced an average volume of 62,361 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Autolus Therapeutics was -1.42 which ended on 30th of September 2018.
Base on our calculations, the intrinsic value per share is 28.00, which means it might overvalued by -39.38%
Indicators Also to Watch:
Based on the latest filings, there is 46.30% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 1.84
PR Newswire: Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)
Fundamental Numbers:
Based on last reported financials, the company’s return on assets is -21.22%, price-to-sales is 1,106.52 and price-to-book is 6.13.
Company Score Card:
Results are out of six:
2 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: AUTL, Autolus Therapeutics, Biotechnology, Healthcare
